How do I tell if SRRK is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Scholar Rock Holding Corporation Common Stock (SRRK) Stock

NASDAQ · SRRK

Trade SRRK

Fundamentals

Market cap

$4.93B

Price / Earnings ratio

-12.5x

Price / Book ratio

20.1x

Return on assets

-87.0%

Dividend amount

$0.00

Dividend yield

0.00%

Source: third-party data provider, as of October 14, 2026

Compare with SRRK

Technical indicators

RSI 14: 26.34
MACD 12/26/9: -2.98
EMA 9 of MACD: -2.48
MACD histogram: -0.50
SMA 50: $51.25; Price below SMA 50
EMA 50: $49.10; Price below EMA 50
SMA 200: $48.32; Price below SMA 200
EMA 200: $47.07; Price below EMA 200

Calculated by Gotrade from daily closing prices, as of October 13, 2026. Technical data, not a recommendation.

Analyst ratings

Analyst consensus: Buy

Based on 10 analyst ratings

Strong Sell0

Sell0

Hold1

Buy8

Strong Buy1

Third-party analyst opinion, not a recommendation from Gotrade.

Financials

Performance

Revenue

Net income

Net margin %

2025

0000

Debt & Balance Sheet

Total assets

Total liabilities

2025

485M320M160M0

Revenue to Profit

2025

$0.0

Revenue

$0.0

Cost of revenue

$0.0

Gross profit

$0.0

Operating expenses

$-377.9M

Net income

Earnings

No data available

Source: third-party data provider

About Scholar Rock Holding Corporation Common Stock

No description available.

SectorHealthcare

IndustryBiotechnology

Employees289

CEOMr. David L. Hallal

IPO DateMay 24, 2018

HeadquartersCambridge, MA

Key Executives

Name	Title	Year Born
Mr. David L. Hallal	CEO & Chairman of the Board	1966
Mr. Vikas Sinha C.A., CPA, M.B.A.	CFO & Treasurer	1963
Mr. Robert Keith Woods	Chief Operating Officer	1968
Dr. Akshay Krishnadas Vaishnaw M.D., Ph.D.	President of R&D, Member of Scientific Advisory Board and Director	1963
Ms. Erin Moore CPA	Interim Principal Financial & Accounting Officer	1975
Ms. Lisa Wyman M.S.	Chief Technical & Quality Officer	1978
Mr. Mo Qatanani Ph.D.	Chief Scientific Officer	1973
Ms. Rushmie Nofsinger	Vice President of Corporate Affairs & Investor Relations	—
Ms. Junlin Ho J.D.	General Counsel & Corporate Secretary	1979
Ms. Caryn Parlavecchio	Chief Human Resources Officer	1972

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021										-3.6	-1.3	-2.1
2022	-27.8	-6.5	-23.8	-47.3	-34.3	+17.8	+28.7	+32.8	-20.3	+37.7	-16.1	+15.0
2023	+26.3	-29.8	-6.7	-24.2	-12.6	+28.0	-3.9	-8.8	+12.9	+80.4	+2.4	+39.8
2024	-20.3	+3.7	+13.3	-12.6	-37.2	-12.1	+11.7	+2.6	-12.0	+281.7	+40.4	+13.9
2025	-8.6	-3.1	-11.3	+9.5	-11.4	+19.0	+9.7	-10.2	+12.4	-14.6	+53.1	+4.9
2026	+3.6	-5.0	+13.1	-5.6	+6.3	+16.1	-10.5	+23.9	-13.5	-12.2

Stocks in the same sector

Vertex Pharmaceuticals

ABEO

Abeona Therapeutics Inc.

FAQ

Buying Scholar Rock Holding Corporation Common Stock (SRRK) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and complete KYC.
Make a deposit.
Search for the code "SRRK", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy SRRK by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in Scholar Rock Holding Corporation Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

At the moment, Scholar Rock Holding Corporation Common Stock (SRRK) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track SRRK's performance via the price chart in the Gotrade app.

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB, or 8:30 PM to 3:00 AM WIB during Daylight Saving Time. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours.

Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trading Lebih Cepat. Lebih Mudah. Lebih Cerdas.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

Scholar Rock Holding Corporation Common Stock (SRRK) Stock

Fundamentals

Compare with SRRK

Recent news

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SRRK Shares Pull Back After FDA Approval For Genetic Disease Drug — But Wall Street Hikes Price Targets

SRRK Shares Pull Back After FDA Approval For Genetic Disease Drug — But Wall Street Hikes Price Targets

Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial

Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial

Second Time’s The Charm: FDA Clears Scholar Rock’s SMA Drug Ahead Of Deadline, SRRK Soars 15% After-Hours

Second Time’s The Charm: FDA Clears Scholar Rock’s SMA Drug Ahead Of Deadline, SRRK Soars 15% After-Hours

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SRRK Shares Pull Back After FDA Approval For Genetic Disease Drug — But Wall Street Hikes Price Targets

SRRK Shares Pull Back After FDA Approval For Genetic Disease Drug — But Wall Street Hikes Price Targets

Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial

Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial

Second Time’s The Charm: FDA Clears Scholar Rock’s SMA Drug Ahead Of Deadline, SRRK Soars 15% After-Hours

Second Time’s The Charm: FDA Clears Scholar Rock’s SMA Drug Ahead Of Deadline, SRRK Soars 15% After-Hours

Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)

Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)

US FDA approves Scholar Rock's muscle weakness drug

US FDA approves Scholar Rock's muscle weakness drug

Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial

Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial

Scholar Rock to Present at Upcoming Investor Conferences

Scholar Rock to Present at Upcoming Investor Conferences

SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing

SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing

Scholar Rock withdraws Europe filing for muscle weakness drug, plans resubmission

Scholar Rock withdraws Europe filing for muscle weakness drug, plans resubmission

About Scholar Rock Holding Corporation Common Stock

Key Executives

Fundamentals

Valuation

Earnings Per Share

Income Statement

Dividend

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trading Lebih Cepat. Lebih Mudah. Lebih Cerdas.

#ReadyGoTrade